Document is current
Any future updates will be listed below
-
Authors
Hench, Jürgen
Hultschig, Claus
Brugger, Jon
Mariani, Luigi
Guzman, Raphael
Soleman, Jehuda
Leu, Severina
Benton, Miles
Stec, Irenäus Maria
Hench, Ivana Bratic
Hoffmann, Per
Harter, Patrick
Weber, Katharina J
Albers, Anne
Thomas, Christian
Hasselblatt, Martin
Schüller, Ulrich
Restelli, Lisa
Capper, David
Hewer, Ekkehard
Diebold, Joachim
Kolenc, Danijela
Schneider, Ulf C.
Rushing, Elisabeth
della Monica, Rosa
Chiariotti, Lorenzo
Sill, Martin
Schrimpf, Daniel
von Deimling, Andreas
Sahm, Felix
Kölsche, Christian
Tolnay, Markus
Frank, Stephan
-
Funding
Funding for this research was provided by:
University of Basel
- License Information
-
More Information
Article History
Received: 25 November 2023
Accepted: 11 March 2024
First Online: 4 April 2024
Declarations
:
: Analysis of microarray-type methylation data was approved by the Ethikkommission Nordwest- und Zentralschweiz (EKNZ; Req-2019-01023). The methylation data from Nanopore sequencing were obtained during routine diagnostics with an in-house validated procedure (accredited by sas.admin.ch SMTS 0037). Report scores were scientifically evaluated. Written consent for those samples that underwent non-diagnostic methylSeq was obtained prior to analysis.
: David Capper holds a patent on DNA methylation-based tumour classification and owns shares of the company Heidelberg Epignostix GmbH. The other authors have no financial or non-financial competing interests to declare.
